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Abstract 
Heart failure is one of the growing causes of death especially in developed countries due to longer 
life expectancy. Although many pharmacological and instrumental therapeutic approaches have 
been introduced for prevention and treatment of heart failure, there are still limitations and 
challenges. Nuclear cardiology has experienced rapid growth in the last few decades, in particular 
the application of single photon emission computed tomography (SPECT) and positron emission 
tomography (PET), which allow non-invasive functional assessment of cardiac condition including 
neurohormonal systems involved in heart failure; its application has dramatically improved the 
capacity for fundamental research and clinical diagnosis. In this article, we review the current status 
of applying radionuclide technology in non-invasive imaging of neurohormonal system in the heart, 
especially focusing on the tracers that are currently available. A short discussion about disad-
vantages and perspectives is also included. 
Key words: Heart failure, cardiac neurohormonal system, nuclear cardiology, SPECT, PET, radio-
tracer. 
Introduction 
Benefiting from great advances in molecular bi-
ology, the understanding of cardiovascular diseases 
including heart failure (HF) has dramatically im-
proved at genomic, transcriptional and proteomic 
levels. They have led to the discovery of promising 
experimental strategies for prevention, diagnosis and 
treatment of cardiovascular disease as well [1]. 
Among them, molecular imaging using radionuclide 
techniques focuses on small scale molecular events 
rather than anatomical alterations (such as in com-
puted tomography (CT), ultrasound, radiography). 
The molecular imaging provides non-invasive meth-
od for the monitoring of functional changes in indi-
vidual organs, with higher sensitivity, specificity and 
the possibility of quantification of these alterations. In 
addition, the rational design of radiotracers makes it 
feasible to bring forth valuable pathophysiological 
information in patients, as well as references and 
guidelines for clinical treatment. Single photon emis-
sion computed tomography (SPECT) and positron 
emission tomography (PET) are well established for 
clinical use for evaluating global and regional myo-
cardial functional information at the molecular levels 
[2]. The advantages and challenges of using molecular 
imaging are: detection of early and treatable stages of 








disease progression; monitoring of treatment efficacy 
and optimization of therapeutic strategies [1]. Neu-
rohormonal model instead of hemodynamic disorder 
has received more and more attention recently, which 
has led to the clinical applications of therapeutics 
targeting sympathetic and renin angiotensin system 
(RAS). Neurohormonal activation is considered as 
compensatory mechanism in HF and maintains per-
fusion to the heart, yet in the meanwhile is also re-
sponsible for the progression of HF [2]. From 
long-term point of view, it is associated with progres-
sive impairment of ventricular function and symp-
toms of HF [3]. For the last few decades, several mo-
lecular imaging applications targeting neurohormo-
nal system have been developed and utilized clini-
cally. Yet at the same time, there are still challenges, 
which must be met before the true potential of per-
sonalized medicine can be fully achieved [4]. Despite 
their critical role in regulation of heart, local neuro-
hormonal statuses of patients are not routinely and 
closely monitored in clinical practice. Beta blockers, 
angiotensin-converting enzyme (ACE) inhibitors and 
angiotensin receptor blockers are clinically applied to 
regulate the neurohormonal levels, but further utili-
zation guidance and dosage recommendation should 
be in depth investigated [5, 6]. So far, there is no ideal 
radiotracer available that can accurately reflect the 
overall function of neurohormonal systems. There-
fore, in order to give the readers a brief touch and 
concise overview of the development of neurohor-
monal imaging, we will mainly review the latest ad-
vances in non-invasive cardiac radioactive tracers 
designed to evaluate pathophysiological functions, to 
enable diagnosis and indication for therapeutic ap-
plications along with the discussion of their ad-
vantages and shortcomings. 
Physiopathological basis for heart failure 
imaging 
HF is a common clinical syndrome, in which left 
ventricular dysfunction triggers compensation via 
neurohormonal activation in order to restore cardiac 
output. These responses become part of the disease 
process leading to a vicious and lethal circle. HF is 
caused by many different diseases that damage car-
diac structure and functions, e.g. coronary heart dis-
ease (CHD), hypertension, diabetes etc. Physiologi-
cally, the heart is regulated and controlled by many 
different neural and hormonal systems, including the 
automatic nervous system, RAS, endothelins, and 
atrial natriuretic peptide (ANP). The neurohumoral 
system is an attractive target for therapeutic investi-
gations [7]. In patients with HF, the decreased cardiac 
output results in an activation of high-pressure baro-
receptors in the heart and blood vessels, which further 
triggers changes in heart rate and efficiency through 
the reflex and regulation of the sympathetic nervous 
system [8]. Moreover, the RAS system is activated due 
to decreased blood flow in the kidney, which is 
caused by reduced pump function. It is characterized 
by the release of renin and the eventual conversion 
into angiotensin II catalyzed by ACE. Angiotensin II is 
involved in sodium and water retention as well as 
vascular constriction [9]. These activations are com-
pensatory mechanisms at the early stage of HF to 
maintain cardiac output; however they also play a 
critical role in the aforementioned vicious circle of 
advanced HF by increasing myocardial energy con-
sumption, afterload and arrhythmias. 
The traditional focus of evaluation and man-
agement of HF has been on hemodynamic abnormal-
ities caused by decreased cardiac output. Much of the 
current attention in research and clinic has turned to 
neurohormonal and molecular pathophysiology. 
These efforts are not only to identify patients with 
abnormal cardiac function, but also and more im-
portantly those “potential” patients who have not yet 
to present with pathologic physiology [10].  
Currently, medications against HF mainly em-
ploy the following strategies: Beta-adrenoreceptor 
blockade, ACE inhibition, angiotensin II receptor type 
1 (AT1) blockade as well as non-pharmacological 
therapy using electrical devices. These show clinical 
evidence in reducing mortality and morbidity in HF 
patients [11, 12]. Beta-blockers antagonize the effects 
of endogenous catecholamines, such as epinephrine 
and norepinephrine (NE), in overall sympathetic 
nervous system, and slow down nerve impulses and 
workload. The main beta-blockers used clinically are 
beta1-blockers due to their predominant distribution 
in the heart. Blockage leads to clinical benefits by 
counteracting the overt noxious effects of increased 
catecholamines level through compensatory feedback, 
while consequently improving survival rates and 
even reversing pathologic cardiac remodeling. How-
ever, it is worth mentioning that the clinical effects 
and therapeutic responses of beta-blockers in patients 
may vary greatly due to age and racial differences (i.e. 
genetic variations) [13, 14]. In addition, both ACE 
inhibitors and AT1 antagonists are used clinically and 
have also generated successful results in hyperten-
sion, HF and post-myocardial infarction. Especially 
the “sartan” (angiotensin receptor blocker) series of 
compounds, such as losartan and valsartan, seem to 
be superior to ACE inhibitors and may offer extra 
benefits with fewer side effects [15]. 
It is noteworthy that these medications do not 
always lead to positive effects in HF patients because 
of dose related side effects. Therefore, to maximize the 
benefits of these available therapies, patients at a high 




risk of death, such as pump failure and sudden car-
diac death (SCD), require accurate risk stratification. 
Personalized evaluation of autonomic nervous func-
tion with non-invasive imaging methods is necessary 
and urgent, as this information could not only im-
prove pathophysiological understanding of HF at the 
individual level, but also to serve as prognostic indi-
cator of therapy applications. 
Sympathetic nervous imaging 
The autonomic nervous system is composed of 
two limbs: sympathetic and parasympathetic, where 
the former one uses NE as the main neurotransmitter 
and the latter acetylcholine. The sympathetic nervous 
system exerts positive inotropic effects, whereas the 
parasympathetic nervous system applies negative 
inotropic effects and chronotropic effects. Sympa-
thetic neurons are widely distributed in the human 
heart, globally in the myocardium and especially in 
the coronary vessels. NE is produced in presynaptic 
neurons, using tyrosine as starting resource through 
dihydroxyphenylanaline and dopamine as interme-
diates (Figure 1). It is transported into the presynaptic 
neuronal terminal vesicles via energy requiring ve-
sicular monoamine transporter (VMAT). The firing 
impulse at the presynaptic neuron leads to the activa-
tion of voltage-dependent calcium channels and vesi-
cles containing NE are released into the synaptic cleft 
via exocytosis. Only a minority of the neurotransmit-
ter binds to the adrenoreceptors (including alpha- and 
beta-adrenoreceptors) for downstream effects, 
whereas the majority of NE is selectively reabsorbed 
into presynaptic neurons via the uptake-1 transporter. 
The uptake-1 mechanism is both energy and sodium 
concentration dependent. At least 94 % of the reab-
sorbed NE is restored again into releasing-vesicles 
while the remainder is metabolized by monoamine 
oxidase (MAO) and released into systematic circula-
tion for further metabolic processing [16]. In addition 
to uptake-1, there is a second reuptake mechanism 
mediated by the so-called “uptake-2 transporter”. The 
uptake-2 mechanism is dominant in non-neuronal 
tissues, for instance cardiocyte and vascular endothe-
lial cells [17]. The procedure is crucial especially in 
ATP depletion situations such as ischemia, simply 
due to the fact that uptake-2 is, unlike uptake-1, en-
ergy and sodium concentration independent. NE is, 
after the uptake-2 mechanism, metabolized into 
3-methoxy-4-hydroxyphenylglycol (MHPG) via nor-
metanephrine (NMN) by catechola-
mine-O-methyl-transferase (COMT) and MAO. Be-
sides neuronal reuptake, there are also a number of 
other regulatory mechanisms controlling the release 
and termination of NE; in particular the al-
pha2-adrenoreceptor at the presynaptic neuron pro-
vides negative feedback for exocytosis.  
 
Figure 1. Biosynthesis and metabolism of norepinephrine. 





Figure 2. Chemical structures of reviewed cardiac radiolabelled tracers in sympathetic nervous system. 
 
Several radiolabeled tracers have been devel-
oped to investigate the sympathetic nervous system 
[18]. Catecholamines and their analogs are applied in 
both SPECT and PET applications, in which they fol-
low the same metabolic cascade and therefore 
providing valuable information regarding patho-
physiologic catecholamine turn over states at pre-
synaptic level. More importantly, analogs of these 
neurotransmitters, which are resistant to certain steps 
of metabolism, can be used to monitor these specific 
steps. 
m-Iodobenzylguanidine (MIBG, Figure 2) is a 
structural analog of NE and was originally developed 
by Wieland and coworkers as a radiotracer for scinti-
graphic imaging studies of adrenergic tumors [19]. It 
is, however, currently also used as a SPECT tracer for 
myocardial sympathetic innervation. Because of its 
relatively specific neuronal extract through uptake-1 
mechanism by presynaptic neurons and accumulation 
in storage vesicles it is also used to monitor presyn-
aptic functions. 123I-MIBG itself does not show phar-
macological activity, neither by activating the 
postsynaptic alpha- or beta-adrenoreceptors nor by 
binding presynaptic alpha2 receptor. MIBG is re-
sistant to metabolic enzymes (i.e. MAO and COMT) 
that are responsible for the metabolism of endogenous 
neurotransmitters. Therefore, uptake of 123I-MIBG in 
patients with HF reflects equilibrium between the 
capacity of storing 123I-MIBG in the presynaptic neu-
ron and of release into the synaptic cleft. Regional 
myocardial distribution of 123I-MIBG shows a clear 
early phase (15 to 30 minutes) initial uptake and de-
layed retention (3-4 hours) with regard to the heart to 
mediastinum ratio, which is basically a measure of 
washout rate. Decreased uptake and retention of 
123I-MIBG may represent increased release of NE from 
presynaptic neuron endings, deterioration of uptake-1 
transporter (due to, for instance, ATP exhaustion), 
decreased density of sympathetic nerve ending, or 
competition with NE (higher concentration of it in 
synaptic cleft). Depending on these possibilities, a 
cardiovascular condition can be suggested accord-
ingly. The ADMIRE-HF study confirmed the inde-
pendent prognostic value of 123I-MIBG imaging in 
patients with NYHA class II and III HF [20]. Negative 
predictive value of cardiac death at 2 years in patients 
with preserved MIBG cardiac uptake was 98.2%. 
One clinical application of 123I-MIBG imaging 
was to identify patients who would benefit most from 
an implantable defibrillator [21, 22]. In a study in-
volving 106 patients with chronic HF, 18 of them died 
during the follow-up period (65 ± 31 months) due to 
SCD, which strongly correlated to the wash out value 
of 123I-MIBG obtained from MIBG imaging [23]. This is 
a useful predictor of SCD in patients with mild to 
moderate chronic HF and at risk of ischemic coronary 
artery disease, who are therefore in great need to be 
treated with an implantable cardiac defibrillator 
(ICD), independently of left ventricular ejection frac-
tion (LVEF). While enrolling 160 HF patients referred 
for ICD therapy, cardiac sympathetic denervation as 
assessed by MIBG can be used to predict ventricular 
arrhythmias and lethal conditions [24]. As a result of 
this, it is possible to prevent those patients who are in 
a need of ICD being overlooked and vice versa who 
do not need the implantation suffering from surgery 
and high cost [25]. 
A study was performed by Merlet et al., which 
included 112 patients with HF resulting from idio-
pathic dilated cardiomyopathy. Within all the factors 
the patients underwent, MIBG uptake is the only in-
dependent one strongly correlated with cardiac mor-
tality during follow-up [26]. In another study involv-
ing 93 patients with chronic HF, planar MIBG imaging 
was performed. The late uptake of MIBG as well as 
peak oxygen consumption turned out to be a critical 




predictor of death or heart transplantation and could 
be used as prognostic indexes [27]. A further study 
reconfirmed the direct correlation between late up-
take of MIBG and the number of non-survivors [28]. 
Moreover, the myocardial washout rate of MIBG is 
one of the best predictors of cardiac death and should 
be taken into consideration for prognosis in patients 
with chronic HF. Those patients with high washout 
rate showed a higher chance to develop into more 
severe conditions or cardiac death [23, 29-31]. In 
summarizing all above factors, a multicenter study 
including eighteen studies with totally 1755 patients 
was performed. The result further confirmed that de-
creased late heart mediastinal ratio or increased my-
ocardial MIBG washout are independently associated 
with the development of worse prognosis [32]. It is 
noteworthy, although MIBG has shown potential to 
predict possible lethal conditions and help determin-
ing the application of ICD or cardiac transplantation, 
studies based on larger population as well as applying 
standardized procedures and criteria should be per-
formed. 
Although MIBG has been used and studied for 
30 years, information is still missing especially with 
regard to drug interference. A study showed that a 
variety of drugs interact with MIBG uptake by five 
mechanisms: uptake-1 inhibition, competition or in-
hibition of active transport to vesicles (by VMAT), 
depletion of neurosecretory vesicle content and cal-
cium-mediated mechanism. It is therefore recom-
mended to pay attention when clinical studies are 
performed, in order to avoid potential bias and to 
improve the efficacy of MIBG scintigraphy as diag-
nostic tool [33]. 
The ephedrine analog 11C-meta-hydroxyephe-
drine (11C-HED, Figure 2) [34] shares similarities to 
123I-MIBG: targeting sympathetic nerve terminals with 
a similar metabolic profile to NE [35]. It is transported 
to the neuronal terminus mostly via the uptake-1 
mechanism, and is resistant to MAO and COMT me-
tabolism. However, instead of storing in vesicles like 
123I-MIBG, the retention of 11C-HED in the myocar-
dium mainly reflects a continuing release and 
reuptake, which allows the quantification of retention 
fraction in myocardial tissue against the arterial input 
function. 11C-HED is one of the most popularly stud-
ied sympathetic nerve PET tracers in human studies. 
Besides the advantages a PET tracer can offer, i.e. su-
perior spatial resolution and sensitivity, the concen-
trations of 11C-HED in blood and myocardial tissue as 
well as the changes over time can also be quantified 
[36]. 
 A study was performed in a group of 21 patients 
to determine whether 123I-MIBG imaging-derived pa-
rameters such as heart-to-mediastinum uptake ratio 
or washout rate are associated with quantitative pa-
rameters achieved from 11C-HED PET. A direct com-
parison between 123I-MIBG SPECT and 11C-HED PET 
with regard to image quality, defect size as well as 
location was also investigated. The results clearly 
showed that applying 11C-HED could generate better 
tomographic imaging. In addition, 123I-MIBG 
heart-to-mediastinum uptake ratio gives a reliable 
estimate of cardiac sympathetic innervation as meas-
ured by 11C-HED PET. Furthermore, despite the close 
correlation in defect size, 11C-HED PET appears to be 
more suitable for assessing regional abnormalities 
than 123I-MIBG SPECT because of better quality im-
ages yielded [35]. 
Additional sympathetic innervation tracers 
evolved from native neurotransmitters include 
11C-epinephrine (EPI) and 11C-phenylephrine (PHEN, 
Figure 2). Although they are both easily metabolized 
by MAO degradation, they still allow assessment of 
both neuronal uptake and vesicular storage using 
PET. Inhibition of MAO results in an increase in my-
ocardial 11C-PHEN retention, which makes it an op-
tion to examine in vivo MAO activity [37]. However, 
due to the unspecific leaking of 11C-PHEN from ve-
sicular storage, it is not sensitive to use as a tracer 
reflecting kinetic progress in heart [38]. A clinical 
study involving 7 healthy volunteers and 10 trans-
plant patients was performed to investigate tracer 
behavior after heart transplantation. Both 11C-HED 
and 11C-EPI showed high selectivity for neuronal up-
take in the heart, but with a significant reduction of 
tracer retention in transplant recipients. Furthermore, 
due to the resistance of 11C-HED to metabolic break-
down, its retention behavior reflects more on the 
presynaptic nerve terminal uptake-1 mechanism, 
while 11C-EPI and 11C-PHEN also depend on other 
factors [39]. 
Overall, the application of 11C-HED gave similar 
information as those applying 123I-MIBG due to com-
parable mechanisms, since both reflect autonomic 
functions of the heart. However, 11C-HED PET pro-
duces improved image quality, the possibility of 
quantification, temporal and spatial resolution when 
compared to the application of 123I-MIBG in SPECT. 
On the one hand, it is superior to use PET imaging 
due to the reasons mentioned above, on the other 
hand, it should be emphasized that the costs for PET 
imaging are much higher than SPECT because of the 
on-set requirement of cyclotron for generating 11C 
isotope. The short half-life of 11C (merely 20 minutes) 
greatly limits its clinical use. Nevertheless, a novel 
18F-labeled PET tracer, 18F-LMI1195 (Figure 2) has 
been recently developed and reported [40]. In com-
parison to 11C PET tracers, 18F tracers provide several 
advantages: these include a longer radioactive 




half-life of approximately 110 minutes, distribution 
from a central cyclotron facility, and higher flexibility 
in the design of synthetic scheme and study protocols 
with delayed or prolonged imaging. Cardiac PET 
imaging with 18F-LMI1195 in rats, rabbits and non-
human primates revealed myocardial uptake with 
low radioactivity levels in the blood, lungs and liver. 
In rabbits pretreated with desipramine, myocardial 
uptake decreased in a concentration dependent 
manner. In nonhuman primates pretreated with 
desipramine, uptake of 18F-LMI1195 in myocardium 
also decreased by 66% [40]. In addition, 18F-LMI1195 
is retained in the heart of rabbits primarily via the 
neuronal uptake-1 mechanism and is selectively asso-
ciated with the NE transporter, similar to 123I-MIBG. 
Therefore, this tracer can be used for evaluation of 
cardiac sympathetic denervation and guidance of an-
tiarrhythmic drug treatment [41, 42]. Interestingly, 
among different species, the cardiac uptake mecha-
nism of 18F-LMI1195 demonstrated significant varia-
bility. In contrast to the results obtained above, car-
diac uptake of 18F-LMI1195 in rats was significantly 
inhibited by phenoxybenzamine instead of desipra-
mine, suggesting 18F-LMI1195 undergoes uptake-2 
mechanism and is consistent with the rat heart where 
this is the dominant mechanism [43]. 
18F-LMI1195 was recently evaluated in a phase 1 
clinical trial involving 12 healthy volunteers. Experi-
mental data regarding human safety, whole-organ 
(myocardial, lung, liver and blood pool uptake) bio-
distribution and radiation dosimetry of 18F-LMI1195 
were performed [44]. The results are encouraging: no 
adverse effects due to 18F-LMI1195 were observed; 
relative quick blood, lung and liver clearance com-
pared to over 4 hours’ stable myocardial uptake, 
providing good target-to-background ratios for car-
diac imaging (Figure 3). These preliminary results, 
similar to 123I-MIBG and 11C-HED, suggest favorable 
dosimetry with high resolution imaging when ap-
plying 18F-LMI1195. 
Although sympathetic nervous tracers like 
123I-MIBG and 11C-HED are under intense investiga-
tion, the abilities of these compounds to provide ac-
curate measurements of cardiac nerve density are 
limited due to their rapid NE transport rates. There-
fore, a set of compounds with phenethylguanidine 
structures, similar to 123I-MIBG were synthesized and 
reported [45]. Among them, 18F-4F-MHPG (Figure 2) 
is an interesting radiotracer, owing to the fact that its 
special kinetic properties are favorable for quantifying 
regional nerve density with PET and tracer kinetic 
analysis. Some of the above compounds demonstrate 
slower uptake by the NE transporter compared to 
123I-MIBG or 11C-HED, and may therefore provide 
additional kinetic information beyond conventional 
imaging agents [46]. 
 
 
Figure 3. Whole-body 18F-LMI1195 coronal images at mid-myocardial 
level in human volunteers. It demonstrated favorable kinetics for cardiac 
imaging: myocardial activity remained stable over 4 hours, with favorable 
heart-to lung and heart-to-liver ration over the same period. 18F-LIM1195 
is rapidly cleared from circulation. Modified from original figure in refer-
ence [44]. 
 
It is noteworthy, when applying 123I-MIBG, 
11C-HED or 18F-LMI1195 and interpreting the data 
achieved, the animal model that is used for the ex-
periment should be considered carefully, due to dif-
ferent uptake-1 and -2 mechanisms presented in dis-
tinct species. Cardiac uptake-2 activity is important in 
the rat, cat and dog, but poorly expressed in the rabbit 
[47]. As a result, MIBG can be a good substrate for 
uptake-2 in rat heart, but will not localize in patients 
because of the negligibility of uptake-2 in human [48]. 
By contrast, HED is a poor substrate for uptake-2 [49]. 
Similarly, LMI1195 shows high selectivity to neuronal 
uptake-1 both in rabbit and human due to the domi-
nancy of this transporter. But in other animal species, 
such as rats, LMI1195 should be used cautiously [42, 
43]. 
Postsynaptic sympathetic nervous function, al-
pha and beta adrenoreceptors, are also important 
elements in the sympathetic nervous system and seem 
promising for functional imaging. But currently, only 
a few beta-adrenoceptor antagonist-derived radi-
oligands have been extensively investigated, such as 
11C-CGP12177 and 11C-CGP12388 [50]. 11C-CGP12177, 
being derived from the beta-receptor antagonist 
3H-CGP12177, was reported for cardiac PET imaging 
due to its high hydrophilicity and affinity to be-
ta-adrenoceptor (Figure 2) [51]. It proved the possi-
bility of investigating changes of beta-receptor density 
in patients, in a condition such as myocardial ische-
mia [51]. Moreover, it is proved to be an indicator of 
post-synaptic function in congestive heart failure 
(CHF) patients [52]. In a study involving ten patients 




with idiopathic dilated cardiomyopathy (IDC), base-
line myocardial beta-receptor density estimated by 
11C-CGP12177 PET was compared with changes of 
LVEF. The receptor density significantly correlated 
with delta changes of LVEF by beta-blocker carvedilol 
as well as plasma NE, which indicates the advantage 
of applying beta-receptor PET tracer for guidance of 
therapeutic practice [53].  
The isopropyl analog of 11C-CGP 12177, i.e. 
11C-CGP12388 (Figure 2), was prepared [54] and also 
evaluated in animals. It shows similar in vivo behav-
ior as 11C-CGP12177, but is relatively easily prepared 
[55]. As a result, using tracer kinetic modeling, 
11C-CGP12388 was assessed in 6 patients. The protocol 
with injections of high specific activity (SA), low SA 
and unlabeled ligands, respectively, was found to be 
the most sensitive protocol with regard to in vivo pa-
rameter changes, which accordingly can be used for 
beta-adrenoceptor density estimation as well [56]. In 
addition, it is proved that the receptor binding of 
11C-CGP12388 was flow independent, with low non-
specific binding [57]. In accordance with the results 
obtained from 11C-CGP12177 study, the investigation 
involving six patients with IDC and six age-matched 
healthy controls using 11C-CGP12388 PET also indi-
cates that it is applicable for the measurement of my-
ocardial beta-receptor density in patients [58]. Other 
tracers concerning beta1-selective ligands or targeting 
alpha-adrenoceptors have also been reported but 
further assessment to confirm specificity and robust-
ness of the assay is still needed [50]. 
Parasympathetic nervous imaging 
In addition to sympathetic nervous imaging 
tracers, some radioligands have also been reported for 
the evaluation of the parasympathetic nervous sys-
tem. But the low density and broad distribution of 
target receptors and rapid degradation of neuro-
transmitter acetylcholine make the development of 
ideal tracers for this system very difficult and de-
manding. Vesicular acetylcholine transporter 
vesamicol has been used to develop a series of tracers, 
but the low rate of specific binding in myocardium 
and rapid washout limited the further development of 
these compounds [59].  
Among all parasympathetic nervous imaging, a 
metabolic stable M2 receptor antagonist 11C-MQNB 
was first introduced and underwent a number of 
studies for the visualization of cardiac muscarinic 
receptors [60]. It showed the distribution of musca-
rinic receptors in different area of human heart [61]. A 
mathematical model, multi-injection protocol appli-
cation of 11C-MQNB was tested on dogs to quantify 
muscarinic receptors in vivo [62]. This method could 
be transferred into a healthy human study, whereas 
the complicated protocol limited broad clinical use of 
this tracer [63]. Even though, a study involving 20 
patients with CHF has further successfully demon-
strated the associated upregulation of myocardial 
muscarinic receptors in these patients [64]. Further-
more, applying 11C-MQNB PET to 11 patients few 
days after myocardial infarction, it was suggested that 
muscarinic receptor density remains within normal 
values in regions containing damaged tissue [65]. 
Not so much work has been done on the plausi-
ble assessment of parasympathetic nervous system 
using tracers derived from acetylcholinesterase 
(AChE) inhibitors. Some 11C-tracers were developed 
by Wang et al. could show rapid heart uptake and 
delineate the heart clearly [66]. Recently, clinically 
used AChE inhibitor derived tracer 11C-donepezil has 
been tested and proved good PET imaging tracer to 
quantify the parasympathetic innervation in the heart 
[67], which might open a gate to cardiac radionuclear 
imaging. 
Renin-angiotensin aldosterone system 
imaging 
In addition to tracers focusing on the autonomic 
nervous system, the RAS has also received attention 
in cardiac imaging due to the fact that it plays a very 
important role in left ventricular remodeling. Angio-
tensin II receptor antagonists were chosen to build up 
the non-invasive assessment of regional activation of 
the RAS, so as to improve the understanding of its 
role in remodeling and to optimize RAS-based phar-
macotherapy. 
The RAS is a hormonal cascade that generates 
angiotensin peptides and is the main regulator of 
blood pressure as well as fluid and electrolyte bal-
ance. When decreased intrarenal blood pressure or 
low sodium and chloride in the kidney are detected, 
renin is released. It acts on angiotensinogen produced 
in the liver to generate a ten amino acid oligopeptide 
angiotensin I. It is afterwards converted to angioten-
sin II through the catalysis of ACE. Angiotensin II is 
considered a major factor and vasoactive hormone to 
increase the blood pressure by stimulating the angio-
tensin II receptor (mainly AT1) [68]. Therefore, in car-
diovascular diseases, such as hypertension or HF, 
either ACE or AT1 receptor antagonists are considered 
valuable therapeutic targets (Figure 4). In recent years 
AT1 receptor antagonists provided a more specific 
blockade of the RAS with virtually no agonist effect 
and better safety compared to ACE inhibitors [69,70]. 
In addition to the circulating RAS, which contributes 
to the systemic regulation of global cardiovascular 
homeostasis, the heart has an intrinsic RAS that me-
diates locoregional mechanisms such as interstitial 
fibrosis, myocyte hypertrophy and apoptosis [71]. 




Activation of the intrinsic myocardial RAS may be 
responsible for structural and functional changes, 
which are hallmarks of HF progression. 
Due to the decisive role that ACE inhibitors play 
in cardiovascular disease treatment, it is very attrac-
tive to develop ACE inhibitor-derived tracers for 
monitoring of disease progress and improving drug 
applications. Lisinopril is a clinically used ACE in-
hibitor for the treatment of hypertension and CHF. It 
was used in ACE imaging from three different ap-
proaches: I-125 labeled benzamidine analog 125I-351A 
[72] and technetium-99m labeled compound 
99mTc-lisinopril [73,74] for SPECT imaging, as well as 
the F-18 labeled benzoyl analog 18F-fluorobenzoyl 
lisinopril [75] for PET imaging (Figure 5). While 
maintaining the inhibition of ACE, they all success-
fully visualized the distribution of ACE while block-
ing studies proved specificity in vivo [76,77]. An 11C 
tracer derived from ACE inhibitor zofenopril (Figure 
5) was reported by Matarrese et al. and evaluated 
first-hand in human. But similar to other ACE tracers, 
the compound accumulated mainly in the organs with 
high levels of ACE, like lungs and kidneys, or liver 
and gall bladder for metabolism reason [78]. There-
fore, the usage of this tracer would be greatly limited 
in the human heart. By applying these tracers, despite 
the nonuniform binding, or distribution of ACE in 
heart, it might be possible to monitor myocardial ACE 
upregulation in the progress of HF and might allow 








Figure 5. Chemical structures of current radiolabeled tracers targeting RAS. 




Compound 11C-KR31173 shows similar binding 
affinity at the AT1 receptor in vitro (Figure 5) as its 
lead compound SK-1080, a non-peptide AT1 selective 
antagonist [79]. It is metabolically stable and demon-
strates promising biodistribution and kinetic proper-
ties in multiple species. Ex vivo biodistribution stud-
ies in mice demonstrated specific binding rates of 
80-90% in the adrenal glands, kidneys, lungs and 
heart. Kidney and liver uptake was observed in mice 
and the uptake competes with SK-1080 [80].  
In a study using a rat myocardial infarction 
model, 11C-KR31173 was used to determine the feasi-
bility of characterizing the presence and time course 
of regional myocardial AT1 receptor upregulation and 
the blocking efficacy of various anti-RAS drugs. Using 
small-animal PET, the increased uptake of 
11C-KR31173 in the infarct area, i.e. transient regional 
AT1 receptor upregulation, was detected with a peak 
at 1-3 weeks after surgery. This effect can be com-
pletely blocked by intravenous SK-1080 as well as by 
using the clinical AT1 blocker valsartan instead of the 
ACE inhibitor enalapril, which clearly confirms the 
AT1 receptor-targeted imaging and provides a ra-
tionale to predict the risk for ventricular remodeling 
and to monitor the efficacy of anti-RAS drug therapy 
[81]. Healthy pig studies also demonstrated myocar-
dial retention of 11C-KR31173, with regional homo-
geneousness and AT1 receptor specificity, as con-
firmed by blocking experiments (Figure 6). Further-
more, first-in-man studies were performed without 
adverse effects. Myocardial retention as well as re-
gional homogeneousness of 11C-KR31173 in cardiac 
imaging was similar to pigs and stable over time yet 
with intense liver uptake. The myocardial retention 
could be selectively blocked with AT1 receptor an-
tagonist olmesartan [82].  
It is worth emphasizing here, that similar to 
sympathetic nervous system imaging, when applying 
RAS system imaging, the species difference should 
also be taken into account, since rat is lack of enough 
amount of angiotensin receptors expressed in myo-
cardiocytes at physiological conditions [83], whereas 
it is expressed in both rabbits and humans. Those 
animal models using rat were applicable after myo-
cardial infarction to visualize active myofibroblast 
during the course of healing process. In humans, the 
level of AT1 receptors in ventricular myocardium 
suggested to decrease in HF as shown in ex-vivo tis-
sue experiments [84,85]. Further in-vivo PET imaging 
in HF patients may provide further insights into dy-
namic and regional information of AT1 receptor func-
tion.  
Endothelin A receptor imaging  
Endothelins (ETs) are a family of natural vaso-
constricting peptides released primarily by endothe-
lial cells. There are three isoforms of ETs: ET1, ET2 and 
ET3. Among them, ET1 is the predominant isoform 
affecting the cardiovascular system by stimulation of 
the subtype A receptor (ETA, a G-protein-coupled 
receptor) on vascular smooth cells and subsequent 
vasoconstrictive effects. The stimulation of the sub-
type B receptor (ETB) by ET1 leads to the release of 
vasodilators such as nitric oxide. In addition, the 
production and release of ET1 as well as the expres-
sion of ET receptors is enhanced during HF [86]. 
Therefore, the use of ET receptor antagonists, mainly 
for ETA, may have a therapeutic effect in patients with 
HF [87].  
Carbon-11 labeled ETA and ETB receptors an-
tagonist and peptide-based L-753037 has been syn-
thesized (Figure 7). Small animal studies have been 
conducted in mice and dogs. Tracer uptake was ini-
tially much higher in liver, lungs and kidneys than in 
heart, yet the radioactivity remained constant in the 
heart for over 2 hours compared to the fast washout in 
other organs. In dog studies, there is also high tracer 
accumulation in the heart, which can be blocked by 
pretreatment of corresponding ET receptor antagonist 
L-753164 [88]. 
 
Figure 6. Stable cardiac uptake of 11C-KR31173 as baseline (A) and blockade by SK-1080 (B) in healthy pig. High specific cardiac tracer accumulation was 
proven. Modified from original figure [82]. 





Figure 7. Radiotracers derived from non-peptide ET receptor antago-
nists. 
 
Figure 8. Chemical structures of ETA receptor radioligands. 
 
18F-SB209670 is a non-peptide ET receptor an-
tagonist with a structure very similar to L-753037 
(Figure 7). It is used to investigate pharmacokinetic 
properties to permit binding and imaging of ET re-
ceptors in rat hearts in vivo. This compound has been 
demonstrated to bind to human heart tissue with 
subnanomolar affinity. Rapid clearance from liver and 
subsequent redistribution to the small intestine was 
observed indicating high levels of hepatic metabo-
lism. Despite this property, visualization of uptake in 
the rat heart in vivo suggests rapid and primary 
binding to ETA receptors [89]. 
Compounds 11C-BMS-5p and 18F-FBzBMS are the 
11C and 18F PET radioligands targeting ETA receptor, 
derived from ETA antagonist BMS-207940, respec-
tively (Figure 8). In mice, both radioligands demon-
strate early uptake in liver, lungs and heart. The ra-
dioactivity in heart and lungs remain relatively stable 
while it decreases in the liver due to wash out. Specific 
binding in the heart was determined to be 63% for 
11C-BMS-5p and 81% for 18F-FBzBMS. Furthermore, 
baboon studies demonstrate high myocardial uptake 
by showing 85% specific binding at 85 min after in-
jection. This specific myocardial uptake can be 
blocked by pretreatment of BMS-207940, which rep-
resents a selective ETA receptor antagonist [90]. 
An in vivo study using 32 healthy rats recently 
confirmed cardiac uptake of 18F-FBzBMS, which could 
be blocked either by intravenous pretreatment of 
BMS-207940 by 93%, or in a dose-dependent (5-100 
mg/kg) partial blockade by the oral administration of 
clinical ETA blocker bosentan (Figure 9). The myocar-
dial uptake of 18F-FBzBMS was preserved in the in-
farct region from day 1 to month 6. Ex vivo analysis 
also confirmed ETA receptor expression in the infarct 
area, where PET imaging partially overlapping with 
CD31 expression on endothelial cells [91].  
It is worth mentioning here that positive results 
of the application of endothelin receptor antagonism 
from animal models of HF were not successfully 
translated into clinical practice as shown in the phase 
3 clinical trial of bosentan. In this trial, treatment of 
chronic HF with bosentan did not reach the expected 
therapeutic endpoint [92]. However, the reasons 
might be complex and need further evaluation. In 
particular, the usage of radionuclide imaging becomes 
more important in this case; determination of optimal 
dose and duration of medication is needed, and so is 
the discovery of the physiopathological principle un-
derlying the distinct therapeutic responses involved 
in post infarct remodeling. Therefore, the application 
of non-invasive monitoring of the endothelin system 
may become more important in helping researchers to 
explore new treatment modalities. 
Summary and perspective 
Personalized medicine tailors medical treatment 
to individual characteristics of each patient and opti-
mize treatments to achieve maximum efficacy with 
minimum harm [93]. Radionuclide imaging contrib-
utes to personalized medicine in five stages: early 
predisposition profiling, monitoring and prevention, 
diagnostics, treatment selection and medication mon-
itoring [94]. It is noteworthy, although therapeutic 
approaches such as ACE inhibitors and AT1 antago-
nists have been applied in patients for a couple of 
decades, the responses to the treatments are highly 
variable [95]. In clinical practice highest pharmaceu-
tical doses are normally recommended, but side ef-
fects are correspondingly increasing with incremental 
doses. Therefore, it will be ideal to have individual 
optimal-effective dose determination strategies for 
patients by applying molecular imaging combined 
with specific radiotracers. Moreover, the 
ADMIRE-HF/HFX trial proved the extra value by 
incorporating the application of 123I-MIBG into the 
selection of appropriate candidate patients for ICD 
implantation. Both cost effectiveness and risk reduc-
tion in this case demonstrated the advantages of uti-
lisation of nuclear imaging [20,96]. It is therefore 
promising to provide specific indications for drug 
responses and to support personalized medicine.  





Figure 9. (A) Autoradiographic short-axis images of 18F-FBzBMS in healthy rat hearts with and without ETA antagonist BMS-207940 pretreatment. (B) 
Effects of medication on cardiac 18F-FBzBMS uptake. Dose dependent blockage by bosentan was shown. *P < 0.001 vs. control. mg/kgw = mg per kg of body 
weight [91]. 
 
In addition to the aforementioned stand-alone 
instruments, i.e. using SPECT or PET alone, the last 
few years have led to the integration and spatial 
co-localization of morphological and functional in-
formation using hybrid imaging, e.g. SPECT/CT, 
PET/CT and so on. These techniques appear to be 
beneficial and provide superior diagnostic and prog-
nostic information compared to previous generation 
imaging agents and techniques. They supply com-
plementary morphological (from MRI or CT) and 
functional information at the cellular and molecular 
level (from SPECT or PET) in a single setting. These 
studies have the potential to be clinically more effec-
tive and to minimize costs. These combinations may 
trace signals addressing molecular and physiological 
aspects of disease phenotype and therapeutic effects 
[97, 98].  
Cardiovascular molecular imaging, in particular 
targeting the neurohormonal system of the heart, is a 
rapidly emerging discipline promising visualization 
of specific molecular targets and pathways, i.e. en-
zymes, receptors or transporters, which precede or 
underlie changes in morphology, physiology and 
function. Particularly due to the high detection sensi-
tivity, non-invasive imaging with PET (using 11C or 
preferably 18F tracers) has become a key player in the 
development and introduction of novel molecular 
imaging approaches [99]. There are several ad-
vantages and disadvantages, which should be ad-
dressed here once again. Advantages include the 
great potential of cardiac imaging to aid in the dis-
covery and development of novel therapies through 
improved target identification, to enhance funda-
mental cardiac research by visualizing cellular and 
subcellular targeted structures, to move forward in 
achieving better sensitivity and image quality as well 
as molecular specificity, and also to act as a key ele-
ment in emerging personalized medicine by distin-
guishing diverse geno- and phenotypical differences 
between cardiac patients [99]. In the Prediction of 
Arrhythmic Events with Positron Emission Tomog-
raphy (PAREPET) clinical study, applying three dif-
ferent tracers to quantify resting perfusion, NE uptake 
and metabolic viability, it is performed in order to 
identify the possible determinants to develop into 
sudden cardiac death [100,101]. However, it is also 
noteworthy, that although PET can achieve better 
imaging quality and is equipped with more radio-




tracer options, the opportunity cost of cyclotron in-
stallation strongly limits its wide application. Fur-
thermore PET/CT systems are more costly than 
standalone CT or SPECT systems. Even though these 
challenges exist, advances in the application of mo-
lecular imaging of neurohormonal systems may play 
an increasingly critical role in eventual diagnosis, 
prognosis and clinical treatment of cardiovascular 
diseases. 
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